Vapotherm Blog

Imagine the Ventilatory Support of NiPPV with the Comfort of Humidified High Flow

Clinicians admitting patients in respiratory distress traditionally have three categories of tools to relieve symptoms. There is oxygen therapy for low severity patients, non-invasive positive pressure ventilation (NiPPV) for moderate distress, and then mechanical ventilation for severe cases of respiratory distress.

trifold image showing a pediatric, neonatal and adult patient

The Seven Types of Patients That Could Benefit from High Velocity Therapy

High Velocity Therapy delivered with Hi-VNI® Technology is mask-free noninvasive ventilation (NIV) for spontaneously breathing patients. It is a viable alternative to NiPPV and can relieve undifferentiated respiratory distress, including hypercapnia and hypoxemia. It is one user-friendly tool that could benefit a variety of patients from neonate to end-of-life.

image of a chest x-ray with one lung being partly white

Treating the Congested Patient with High Velocity Therapy

Whether it’s pneumonia, bronchiolitis, or other respiratory infections, secretion clearance is one of the keys to symptom relief. Rehydration of airway mucosa to promote mucociliary function helps with secretion clearance, and this can be effectively achieved by inhalation of heated, humidified gas.

image of a swaddled newborn wearing a Vapotherm cannula

Study Shows Clinicians Using Vapotherm® Oxygen Assist Module Prototype Significantly Better at Achieving Target SpO2 in NICU than Manual Titration

In November 2018, the Archives of Disease in Childhood: Fetal & Neonatal edition published the results of a prospective, two-center, order-randomized cross-over study performed at two NICUs in the UK, designed to evaluate the performance of Vapotherm’s® forthcoming Oxygen Assist Module (OAM) technology.

Rethinking Ventilation

Rethinking Ventilation — Do you always need pressure?

The frequent-flyer COPDer comes into the hospital, dyspneic and tripoding and the respiratory therapist is readying the non-invasive positive pressure ventilation (NiPPV) — this is a frequent sight for clinicians admitting respiratory distress patients. NiPPV has been the gold standard treatment for patients with hypercapnia. It reduces the risks associated with mechanical ventilation while also being more tolerable for the patient.

Image of a busy hospital corridor

Five Reasons Your Hospital Should Try High Velocity Therapy

High Velocity Nasal Insufflation (HVNI) is Mask-Free Noninvasive Ventilation pioneered by Vapotherm® for the treatment of undifferentiated respiratory distress in spontaneously breathing patients. Here are a few benefits that hospitals, clinicians, and their patients may experience with this breakthrough at the frontlines of respiratory care.

faint image of a doctor speaking with a patient behind the letters US Food and Drug Administration

FDA Grants Vapotherm’s De Novo Request for New Category for Precision Flow Hi-VNI System

The U.S. Food and Drug Administration (FDA) granted Vapotherm’s request for a new category (QAV), and expanded indications for the latest version Precision Flow, the Precision Flow Hi-VNITM system. The indication now states this system may be used to augment breathing of spontaneously breathing patients suffering from respiratory distress in the acute setting.

Image of a patient taking oral medication while on Vapotherm high velocity therapy

What is Mask-Free NIV?

For patients in respiratory distress, non-invasive positive pressure ventilation (NiPPV) has been the first-line approach for decades. It’s a respected standard of care, but not all patients can tolerate this mask-based therapy.

Close up image of a Precision Flow system’s screen

How to Select Clinically Effective Liter Flows for Hypercapnic Patients?

Vapotherm’s Hi-VNI® Technology can be used to treat respiratory distress in hospital settings. Vapotherm does not practice medicine or provide medical services. These guidelines are based on an assessment of peer-reviewed published literature, physician interviews, and physiological modeling. Providers should refer to the full indications for use, operating instructions, and prescribing information of any products referenced herein before prescribing them.

Image of a hospital room with a patient in the distance and a vitals monitor in the front

New Randomized Controlled Trial Recommends Vapotherm High Velocity Therapy as Front-Line Tool for Patients Admitted to ICU with Severe Bronchiolitis

In June 2018, Ergul and colleagues published the results of a single-center, randomized controlled trial in the European Journal of Pediatrics titled “Using a high-flow nasal cannula provides superior results to OxyMask delivery in moderate to severe bronchiolitis: a randomized controlled study.”